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Abstract
The current policy concerning cervical cancer screenings is not effectively
addressing the specific needs of the female South African population. The program, as
outlined by the South African Department of Health, is not sufficiently accessing women
due to problems in availability, access, organization, and education. As women are living
longer with HIV/AIDS, due to antiretroviral (ARV) treatment, they are becoming more
susceptible to opportunistic infections that can lead to cervical cancer, such as Human
strains of the virus can be prevented with administration of an HPV vaccination and
advancement of precancerous lesions can be detected and treated with current
technology. Cervical cancer screenings and HPV vaccinations are expensive, however,
and many women are not properly educated about their gynecological options in South
Africa.
The staff at the Khayelitsha Cervical Cancer Screening Project in the Khayelitsha
township of Cape Town provides effective, women-friendly services to the community,
offering cervical cancer screenings and tertiary-level treatment to the women of the
township. In addition to providing a much-needed service to the community, the Project
works as a research facility and is currently exploring the safety of HPV vaccinations on
HIV-positive women in order to promote further research and awareness concerning
cervical cancer and HPV. This study aims to describe the status of cervical cancer
screenings in South Africa and explore the advances made by the center to better
women’s health.
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Introduction
Cervical cancer is the second most prevalent form of cancer to affect women in
South Africa, with 6,700 women developing the disease and more than half of those
dying annually 1 . It is the most common cancer to affect black women, 2 accounting for
25% of cancer deaths, and more than half of the deaths in the world attributed to cervical
cancer occur in developing countries 3 . In addition, women who are HIV-positive are
thought to be three to five times more likely to develop cervical lesions that could
become cancerous 4 . This is because women who are HIV-positive are more susceptible
to opportunistic infections, such as cervical cancer, and have an increased risk of
contracting the Human Papillomavirus (HPV) 5 , which is present in 99.8% of cervical
cancer cases. This creates a high-risk environment for the acquisition of cervical cancer
in South Africa where approximately 13.3% 6 of the female population is living with
HIV/AIDS.
Previously during apartheid, there was no national policy concerning
Papanicolaou (pap) smears, which is a screening test to detect malignant and
premalignant cells in the ectocervix. In the early 1990s, after the end of apartheid, the
South African Department of Health developed the Cervical Cancer Screening Program,
which allows for three free pap smears per lifetime in 10-year intervals, starting at the age
of 30 7 . This plan was implemented because it was considered cost-effective, due to

1

Stevens, M., Bomela, N., ‘cervical cancer- is vaccination the way to go?” Democratic Nursing Organization of South Africa, Nursing
Update, May 2008, p. 37
2
Ibid.
3
Global HIV/AIDS news and Analysis, “South Africa: Cervical cancer vaccine offers distant hope.” PlusNews,
http://www.plusnews.org, June 19, 2007.
4
Ibid.
5
Stevens, M., Bomela, N., ‘cervical cancer- is vaccination the way to go?” Democratic Nursing Organization of South Africa, Nursing
Update, May 2008, p. 37
6
South Africa: HIV and AIDS Statistics, http://www.avert.org/safricastats.htm, Avert, 2008
7
Department of Health, “National Guideline on Cervical Cancer Screening Programme,” Date unknown
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limited resources, and safe because women with at least one negative cervical Pap smear
have low rates of invasive cancer for ten or more years 8 . About 20-30% 9 of women in
South Africa over the age of 30, however, make use of the cervical cancer screenings.
This may be due to lack of public reproductive education surrounding cervical cancer or
discomfort due to the invasive nature of the procedure. Currently, most healthcare
resources are dedicated to the overwhelming burden of disease such as HIV/AIDS and
tuberculosis, while health concerns surrounding issues such as cancer have faltered.
South Africa has yet to effectively address cervical cancer as a legitimate issue.
The percent of cancer deaths due to malignant neoplasm of the cervix uteri has risen from
7.6% in 2001 to 8.1% in 2005 10 , suggesting that the implemented screening program is
not effective in curbing the incidence of cervical cancer among women in South Africa.
This situation is further exacerbated by the HIV/AIDS epidemic in South Africa, where
women are developing fast-growing cervical cancer at younger ages. Professor Lynette
Denny and her team of women at the Khayelitsha Cervical Cancer Screening Project, a
research institution in a township outside Cape Town, are providing women in the
community with cervical cancer screening services, training, education, and transport to
enable women to better access the gynecological services that they should be entitled to.
The Khayelitsha Cervical Cancer Screening Project is also currently studying the effect
of HPV vaccinations on HIV-positive women. The HPV vaccination, which protects
against HPV strains responsible for 70% of cervical cancer cases 11 , currently costs

8

Alliance for Cervical Cancer Prevention, “Cervical cancer Prevention Fact Sheet,” ACCP, 2003
Stevens, M., Bomela, N., ‘cervical cancer- is vaccination the way to go?” Democratic Nursing Organization of South Africa, Nursing
Update, May 2008, p. 37
10
Day, C., Gray, A., “Health and Related Indicators,” South African Health Review 2007, Health Systems Trust, 2007, p. 274
11
Cervarix, http://www.cervarix.com
9
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$360 12 . According to Professor Denny, "If made widely available, it has the potential to
reduce cervical cancer by at least 70 percent - probably more - and is going to be much
more implementable than screening, but it is currently too expensive. 13 ” The cervical
cancer screening and HPV vaccination systems currently in place do not acknowledge the
rising threat that cervical cancer poses for women, especially those living with HIV. As
HIV-positive women are living longer due to antiretroviral treatment, it is necessary to
look at the opportunistic infections, such as cervical cancer, that will affect HIV-positive
women in the future and invent creative solutions to combat this looming threat.

Methodologies
Primary Sources
The information presented in this study is drawn from an array of primary and
secondary data relevant to the topics of cervical cancer and prevention in South Africa,
and specifically to the research and services provided by the Khayelitsha Cervical Cancer
Screening Project based in Khayelitsha. Primary data was obtained through guided
interviews, informal conversations, and participant observation at the Khayelitsha
Cervical Cancer Screening Project, the Khayelitsha Site B Day Hospital, Groote Schuur
Hospital, the University of Cape Town School of Medicine, the African Organization for
Research and Training in Cancer (AORTIC), and youth clinics in the townships
surrounding Cape Town. In the Khayelitsha Cervical Cancer Screening Project, a
research organization based in the peri-urban township, Khayelitsha, information was
acquired through participating in the patient recruitment process with community health
12

Global HIV/AIDS news and Analysis, “South Africa: Cervical cancer vaccine offers distant hope.” PlusNews,
http://www.plusnews.org, June 19, 2007.
13
Ibid.
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workers, observing health practitioners perform cytologic screenings and colposcopic
examinations, organizing patient files, and attending preliminary screening appointment
for prospective study patients. Members of the Project were also important educational
resources concerning past and current research studies, cervical cancer, and the
community. Facilitated interviews and informal conversations with the principle
investigator, project coordinators, nursing sisters, and community health workers were
also useful in obtaining data on the research and services provided by the Project as well
as information concerning the current status of gynecological and general health services
offered in South Africa.
Additional data was obtained through other organizations and institutions in the
Western Cape that specialize in cervical cancer screening advocacy and education.
Informal conversations and interviews were conducted at Groote Schuur Hospital, a statefunded facility that works in conjunction with the University of Cape Town Medical
School, which shed light on the conditions of tertiary level facilities in the Western Cape.
Interviews and discussions were facilitated at AORTIC with Belmira Rodrigues, the
Africa Operations Manager, which was important to understand the large-scale initiatives
to educate African communities about and advocate policy concerning cervical cancer.
Other primary sources included informal conversations with patients and study
subjects from the Khayelitsha Cervical Cancer Screening Project, the Khayelitsha Day
Hospital, and Groote Schuur Hospital to understand the views of the community
concerning cervical cancer screening policies and patients’ attitudes towards reproductive
health. All patients spoken to were middle-aged Xhosa-speaking women from
predominantly poor backgrounds who lived in and around the township of Khayelitsha.

10
For ethical reasons, the names of the respondents spoken to at the hospital are not used
because a woman’s reproductive and sexual health should remain a private matter.

Secondary Sources
Supplemental data included scholarly journals, research articles, books,
pamphlets, and posters. Journals and articles were obtained through recommendations by
the staff at the Khayelitsha Cervical Cancer Screening Project and online databases such
as EBSCOhost and Google Scholar, which are peer-reviewed and considered legitimate
search engines. Other articles were obtained through organizations that advocate for
reproductive health and cervical cancer awareness, such as EngenderHealth, the
European Cervical Cancer Association (ECCA), the Global Alliance for Vaccines
Initiative (GAVI), Instituto Catala d’Oncologia (ICO), the International Agency for
Research on Cancer (IARC), the International Federation of Gynecology and Obstetrics
(FIGO), and Jhpiego. All publications used for this study pertain to cervical cancer, with
an emphasis on screening and treatment methods and policy implementation.
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I. Epidemiology and Natural History of Cervical Cancer
Biology of the Cervix
The cervix is the lower portion of the uterus that meets the upper portion of the
uterus. It is cylindrical in shape and contains a slender canal that connects the vagina with
the inside of the uterus. The cervix plays an instrumental role in many female
reproductive processes, including menstruation, fecundity, childbirth, and pleasure.

QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.

Figure 1.1: Gross anatomy of the cervix 14

The major physiological components of the cervix consist of structures
differentiated by location and cellular structure (Figure 1.1). The upper half of the cervix
located above the vagina is known as the supravaginal portion, which meets the uterus at
the internal os. The lower half of the cervix that protrudes into the vagina through the
anterior wall is known as the portio vaginalis, which opens into the vagina through the
external os. The visible portion of the cervix exterior to the external os is known as the
ectocervix, and is easily seen through the vaginal canal. The portion around the external
14

Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual inspection with acetic acid (VIA) and with
Lugol’s Iodine (VILI)” A Practice manual on Visual Screening for Cervical Neoplasia, Chapter 1, p 2, 2003
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os including the canal that leads to the uterus is known as the endocervix. The cervical
stroma consists of dense, fibrous tissue containing vascular, lymphatic, and nerve
supplies to the cervix, with extensive sensory, sympathetic and parasympathetic nerve
endings lie within the endocervix.
The cellular composition of the endo-and ectocervixes consists of stratified
squamous and columnar epithelium. The stratified squamous epithelium spans several
layers and consists of glycogen-rich cells with small nuclei and make up a major part of
the ectocervix. The thin layer of epithelial cells line the endocervical canal and secrete
mucus that lubricate the cervix and vagina. The columnar epithelium meets the squamous
epithelium at the squamocolumnar junction, whose location changes depending on
factors such as age and hormonal status. The maturation process of the cervix begins
during childhood, where the squamocolumnar junction is located close to the external os.
The cervix enlarges and the endocervical canal elongates during puberty, exposing more

QuickTime™ and a
TIFF (LZW) decompressor
are needed to see this picture.
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Figure 1.2: A schematic diagram of further maturation
of immature squamous metaplasia 15 . Note that healthy
immature squamous metaplasia develops into mature
squamous metaplastic epithelium, while infection with
high-risk HPV types can lead to the growth of atypical
squamous epithelium, which can develop into
precancerous lesions.

Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual inspection with acetic acid (VIA) and with
Lugol’s Iodine (VILI)” A Practice manual on Visual Screening for Cervical Neoplasia, Chapter 1, p 7, 2003.
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columnar epithelial cells. During this ripening stage, the squamocolumnar junction is
located in the ectocervix and is displaced from the external os. Eventually over time,
however, the acidic vaginal environment destroys the columnar epithelial cells, which are
replaced by new, metaplastic squamous epithelium. Through the reproductive period of a
woman’s life, the squamocolumnar junction moves back towards the external os, due to
the replacement of columnar epithelial cells with squamous epithelial cells. During this
process, immature metaplastic squamous epithelial cells can develop into two cell types
(Figure 1.2). In most women, they grow to be healthy, mature squamous epithelium. In
some instances however, immature squamous epithelium can progress to dysplastic, or
abnormal, squamous epithelial cells due to infection with some forms of human
papillomavirus (HPV). This is the first step to the progression of precancerous cervical
lesions, and in some cases, invasive cancer.

Human Papillomavirus and Cervical Cancer
Infection with high-risk types of HPV is considered to be the major risk factor
associated with the development of cervical cancer. Approximately 99.7% of cervical
cancer cases are associated with infection with one or more types of HPV 16 , with 60% of
cancer-related infections due to HPV type 16 (HPV-16) and an additional 10% due to
HPV type 18 (HPV-18) 17 18 . The virus works by integrating its viral genome into the
chromosomes of the host cell, thus leading to the formation of cervical neoplastic cells 19 .

16

Jhpiego, “Jhpiego: Preventing cervical cancer through cost-effective, innovative approaches.” www.jhpiego.org, date unknown.
Tan, J., “Prospects for a vaccine to prevent cervical cancer.” Preventing Cervical Cancer in Low-Resource Settings: From Research
to Practice, Jhpiego, p. 33 2006.
18
Other high-risk types of HPV associated with CIN include 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68.
19
Villa, LL, “Biology of genital human papillomaviruses.” International Journal of Gynecology and Obstetrics, Supplement 1,
Chapter 1, S4, 2006.
17
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Cervical neoplastic cells are almost always seen in the transformation zone 20 where
columnar epithelial cells are being replaced by squamous metaplastic cells. The
immature, undifferentiated squamous cells are the ideal targets for viral coercion and so it
is during the reproductive period of a woman’s life that she is most at risk for developing
atypical cervical growth due to HPV infection. It has been shown that a product of HPV
viral genes E6 and E7, oncoproteins E6 and E7 will bind and inactive cell tumor
suppressor proteins p53 and pRB, which can lead to malignant conversion 21 . It has also
been shown that chromosomal instability occurs in cells expressing these oncoproteins,
including monosomies, chromatid gaps, and aberrant chromosomes 22 . These
chromosomal changes can lead to cervical intraepithelial neoplasia (CIN), which is
characterized by enlarged nuclei, irregularities in nuclear contour, and decreased
cytoplasmic content. While most of these HPV-induced cellular irregularities regress to
normal, if left untreated they may progress to CIN, characterized by varying degrees of
squamous intraepithelial lesions (SIL) and dysplasia leading ultimately to invasive
carcinoma (Table 1.1). 23 Without any intervention, about 50% of cases of high-grade SIL
progress to cervical cancer. 24

20

Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual inspection with acetic acid (VIA) and with
Lugol’s Iodine (VILI)” A Practice manual on Visual Screening for Cervical Neoplasia, Chapter 1, p 8, 2003.
Villa, LL, “Biology of genital human papillomaviruses.” International Journal of Gynecology and Obstetrics, Supplement 1,
Chapter 1, S4, 2006.
22
Ibid., p. S4.
23
Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual inspection with acetic acid (VIA) and with
Lugol’s Iodine (VILI)” A Practice manual on Visual Screening for Cervical Neoplasia, Chapter 1, p 10, 2003.
24
Sankaranarayanan, R., “Epidemiologiy of cervical cancer in developing countries.” Preventing Cervical Cancer in Low-Resource
Settings: From Research to Practice, Jhpiego, p. 8, 2006.
21
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Classification System for Cervical Intraepithelial Neoplasia (CIN)
CIN Type
Dysplasia

CIN I
Mild Dysplasia

CIN II
Moderate Dysplasia

Low-grade
High-grade
intraepithelial lesion
intraepithelial lesion
(LSIL)
(HSIL)
Table 1.1: The Relationship between CIN and the Bethesda System 25
Bethesda Classification

CIN III
Severe Dysplasia
(Carcinoma in situ)
High-grade
intraepithelial lesion
(HSIL)

Some symptoms of advanced invasive carcinoma include “intermenstrual
bleeding, postcoital bleeding, excessive seropurulent discharge, recurrent cystitis,
backache, lower abdominal pain, oedema of the lower extremities, obstructive uropathy,
bowel obstruction, and breathlessness due to severe anaemia and cachexia 26 .” As the
cancer progresses, it spreads to various organs, uncluding the vagina, bladder, and
rectum. Renal failure is also common because the ureter is compressed by the invasive
tissue, causing ureteral obstruction. 27 The survival rate of women with Stage 1A
carcinoma, characterized by cancerous invasion limited to the cervix, is 96-99%. If the
cancer is diagnosed in stage IV, in which the cancer has spread to distant organs, the
survival rate is 15-20% 28 . These statistics suggest that if caught early, cervical cancer is
easily managed, while if left untreated, cervical cancer is fatal within 2 years for 95% of
presented cases 29 .

Immunity and Cervical Cancer
Cervical cancer develops slowly and can take anywhere from 10 to 20 years to
develop from precursor to invasive carcinoma. Young women under the age of 30
typically present with low-grade precancerous lesions, however 90% of these lesions
25

Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual inspection with acetic acid (VIA) and with
Lugol’s Iodine (VILI)” A Practice manual on Visual Screening for Cervical Neoplasia, Chapter 1, p 9, 2003
26
Ibid., p 11.
27
Ibid., p. 12.
28
Stage Information. Cervical Cancer (PDQ): Treatment. National Cancer Institute, May 18, 2006.
29
Sanghvi, H., “Addressing the challenges of treating cervical cancer.” Preventing Cervical Cancer in Low-Resource Settings: From
Research to Practice, Jhpiego, p. 35, 2006.
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regress to normal 30 . Lesions in women who are over 30 years of age, however, are more
likely to advance to high-grade precancerous lesions, with the mean age of women
presented with high SIL being 30 years of age 31 . The control of precancerous lesions is
mediated by both “innate and adaptive immune responses 32 ” with cellular immune
responses being the most important in controlling lesions caused by HPV. Professor
Lynette Denny, the Principle Investigator of Gynecology Oncology Unit in the Institute
of Infectious Disease and Molecular Medicine at University of Cape Town, commented
that “There’s much more HPV-related disease in HIV-positive women and that’s because
to clear the HPV infection, you need what is called cell-mediated immunity, which is
precisely the immunity that the HIV virus attacks. 33 ” Lesion persistency, therefore, is
associated with “genetic, iatrogenic, or acquired cell-mediated immune deficiencies 34 ”,
such as human immunodeficiency virus (HIV) and autoimmune deficiency syndrome
(AIDS). There is a higher prevalence of HPV infection in women who are HIV-positive
than those who are HIV-negative. In a study conducted by Cu-Uvin et al. examining the
prevalence of cervical HPV in over 1,000 women through the HIV Epidemiology
Research (HER) study, the prevalence of HPV infection in HIV-positive women was
64% as opposed to 28% in HIV-negative women 35 . Duerr et al. reinforces Cu-Uvin’s
study by examining the presence of abnormal cell growths found in the HER and found
that cervical intraepithelial neoplasia was present in 19% of HIV-positive women and 5%

30

Department of Health, “National Guideline for Cervical Cancer Screening Programme,” p. 7, date unknown.
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in HIV-negative women 36 . Despite this data, the South African Department of Health
states “to date, studies on the association between invasive cancer of the cervix and HIV
infection are inconclusive. 37 ” Studies strongly suggest that immune responses necessary
for the regression of low-grade cervical lesions caused by HPV is jeopardized in women
who are HIV-positive and according to Jhpiego, a research organization affiliated with
Johns Hopkins University, “co-infection with HIV is associated with a five- to tenfold
increase in severe dysplasia and carcinoma in situ, the precursors of invasive cervical
cancer. 38 ” This relationship between HIV infection and development of precancerous
cervical lesions is especially pertinent to South Africa, where 13.3% of the female
population is living with HIV/AIDS 39 .

Related Risk Factors and Trends in Cervical Cancer Incidence
Other factors that increase the risk of developing precancerous lesions include
“multiple sex partners, multiparity, long term oral contraceptive use, tobacco smoking,
low socioeconomic status, infection with Chlamydia trachomatis, micronutrient
deficiency, and a diet deficient in vegetables and fruits40 .” There are 275,000 deaths
annually due to cervical cancer, with 80% of these fatalities occurring in the world’s
poorest countries 41 . The high incidence of cervical cancer in developing countries may
also be attributed to the poor allocation of resources and lack of cervical cancer screening
programs in place. In South Africa, the incidence of cervical cancer in women of all ages
36
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is approximately 30.2 42 , as opposed to the world incidence of 16 43 44 . In addition, the
cervical cancer mortality rate is 16.5 as opposed to the world mortality rate of 8.9 45 . With
incidence and mortality rates in South Africa about twice as high as those for the world
population, it seems apparent that cervical cancer interventions for the country are not
sufficient to handle the burden of the disease. With regular screenings and proper
treatment methods, cervical cancer is preventable. Unfortunately, a large number of
cervical cancer cases presented in these countries are diagnosed in advanced stages and
thus have poor survival rates 46 .

II. Cervical Cancer Prevention
Primary and Secondary Prevention of Cervical Cancer
Cervical Cancer is both a preventable and treatable disease. Prevention of cervical
cancer is categorized by primary and secondary efforts to curb the incidence of cancer.
Primary prevention eliminates the possibility of obtaining disease. In the case of cervical
cancer, one would prevent its acquisition by eliminating the risk of being infected with
HPV. This can be achieved either by abstaining from sexual intercourse or through an
HPV vaccination. While regular condom reduces the chances of contracting HPV by
70% 47 , the virus is spread through contact of genital organs and does not involve sexual
penetration. Condoms protect only the penis and leave other areas of the genitalia
susceptible to contracting HPV. Secondary prevention stops the progression of the
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disease once the individual has already become infected. Routine screenings for cervical
cancer precursors followed by appropriate treatment is an effective preventative measure
in curbing the incidence of cervical cancer.
Cervical screening techniques are most commonly performed through cytologic
tests, also known as Papanicolaou (pap) smears. Screening involves exposing the cervix
with a speculum and collecting cervical cells using an Aylesburg spatula, which
effectively collects cells from the squamous epithelium and transformation zone where
cervical abnormalities are most common. Collected cells are smeared and fixed on a
slide. Prepared slides are sent to a laboratory where they are analyzed under a
microscope. Cytologic testing is shown to be moderately sensitive and highly specific in
detecting HSIL 48 , however this depends on the purity of the sample and the skill of the
technicians who read the slides. Women are referred for a colposcopy if there are any
atypical cells found in the cytologic testing. In this procedure, a healthcare provider
inspects an illuminated and magnified cervix with a colposcope and takes a biopsy of
suspected lesioned tissue for pathological examination. If CIN is found in the biopsy, the
woman is referred for CIN treatment, which currently includes cold knife conization,
hysterectomy, large loop excision of the transformation zone (LLETZ) 49 , laser ablation,
electrofulguration, and cryotherapy 50
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Successful Interventions in Developed Countries
An example of a successful cervical cancer screening intervention was examined
in the 1960s by the International Agency for Research on Cancer (IARC) 51 . The
organization examined mortality trends associated with cervical cancer and the
effectiveness of well-organized screening programs in the Nordic countries- Denmark,
Finland, Iceland, Norway, and Sweden. The cumulative mortality rates for all of these
countries fell between the years of 1965 and 1982. The most drastic decrease occurred in
Iceland, which had the widest target age range for screening, where mortality rates fell
84%. The cervical cancer intervention included cytologic testing and referral for
colposcopy and treatment if atypical squamous cells were found.
The American College of Obstetrics and Gynecology 52 recommends that women
receive their first cytologic screening 3 years after first sexual intercourse or at age 21,
whichever event comes first. They also suggest that women receive cytologic screenings
yearly until the age of 30, in which women can begin receiving screenings every 2 to 3
years. They do not suggest an upper age limit to stop cytologic screenings, however they
do comment that post-menopausal women have a lowered risk of developing abnormal
cervical cells. Different guidelines apply for women who are HIV-positive. For example,
women are screened with cervical cytology and if results are normal, then the screening
is repeated 6 months later. If the results of the second cytologic evaluation are still
normal, the patient can begin annual screenings. There are, however, no guidelines for
how long HIV-positive women should be screened annually, but Joel Palefsy, an
infectious disease specialist at University of California-San Francisco, suggests that “it
51
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seems reasonable to continue annual screening for a long time, if not indefinitely,
because these women are at especially high risk for persistent HPV infection, acquisition
of new HPV types, or reactivation of previously latent HPV types. 53 ” The American
Society for Colposcopy and Cervical Pathology (ASCCP) guidelines suggest that HIVpositive women be referred routinely for colposcopy if found to have atypical squamous
cells of undetermined significance (ASC-US) upon cytologic evaluation 54 .
Cervical cancer screening interventions are successful in developed countries
because they possess the infrastructure to implement these programs. Women generally
have access to regular and repeated screenings, which is important because of their
moderate sensitivity. Developed countries also possess the technology and trained
laboratory analysts to process cytologic screenings. Access to reliable communication
outlets is also important in that women can be contacted for follow-up treatment or
referrals. Effective cytologic screening requires “lab infrastructure, trained
cytotechnologists and pathologists for processing slides and reporting, internal and
external quality control, and a system for communicating the results to the women. High
quality training, continuing education, and proficiency testing of personnel are essential
to ensure reliable testing. 55 ” There are even more requirements for effective CIN
treatment, including access to colposcopy and surgical equipment.
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III. Cervical Cancer Screenings in the Context of South Africa
South African National Policy Towards Cervical Cancer Screenings
The South African Department of Health entitles women to 3 free pap smears per lifetime
in 10-year intervals beginning at the age of 30 56 . Women screened for the first time at age
55 or more will only have one pap smear in their lifetime if the first smear is normal.
Screenings for diagnostic purposes, however, would be free for the patient since it is not
included in the regular screening scheme. The total cost for cytologic consultation and
laboratory analysis amounts to about R100 – 200 per visit 57 , and due to the burden of
other diseases, such as HIV/AIDS and TB, the South African government is unable to
provide women with free, annual pap smears at clinics and hospitals. The current policy
is based on research from Europe in the 1960s 58 59 (Table 3.1). Researchers found from
the study that if women were given pap smears annually between the ages of 35 and 65,
therefore providing them with 30 cytologic screenings in their lifetime, it would reduce
the cumulative incidence of cervical cancer by 94%, while if one were to provide
cytologic screenings every 3 years, therefore allowing women to have 10 free cytologic
screenings, it would reduce the cumulative incidence by 91%. “94% and 91% are
statistically similar,” says Professor Denny, “so really the ideal screening interval is three
yearly 60 ,” as recommended by the American College of Obstetrics and Gynecology. It
has also been found that if women are screened every 10 years, therefore allowing them 3
screenings in a lifetime, the cumulative incidence of cervical cancer is reduced by 64%,

56

Jhpiego, Cervical Cancer in Low-Resource Settings: From Research to Practice, Jhpiego,, 2006.
Lynch, K. Observation at the Khayelitsha Cervical Cancer Screening Project, April
58
Denny, L. Personal Interview conducted by Kirsten Lynch. Groote Schuure Hospital, Observatory, Cape Town, 1:30 pm, April 21,
2009.
59
Department of Health, “National Guideline for Cervical Cancer Screening Programme, p. 5, date unknown.
60
Denny, L. Personal Interview conducted by Kirsten Lynch. Groote Schuure Hospital, Observatory, Cape Town, 1:30 pm, April 21,
2009.
57

23
which is still a significant decrease in the acquisition of the disease. This screening
system is believed to be the most cost-effective policy for cervical cancer screenings in
the country 61 . There is no national policy in place regarding cervical cancer screenings
for HIV-positive women; however, the Western Cape recommends that HIV-positive
women receive annual cervical cancer screenings.

Relationship Between Number of Pap Smears and Incidence of Cervical Cancer
Number of years between Pap
Total number of smears per
Reduction in cumulative
smears
lifetime
incidence of cervical cancer (%)
1
30
94
3
10
91
5
6
84
10
3
64
Table 3.1: Data the South African Department of Health used to create their cervical cancer screening
policy 62

Effectiveness of the Implemented Policy
Theoretically, since the implementation of the current South African national
health policy for cervical cancer screenings, there should be a 64% decrease in the
cumulative incidence of cervical cancer in the country, but only if 100% of the female
population is being screened. The national target is to screen at least 70% 63 of women
nationally, however only 20 – 30% 64 of women are currently accessing these services.
The percent of cancer deaths due to malignant neoplasm of the cervix uteri has risen from
7.6% in 2001 to 8.1% in 2005 65 , suggesting that the implemented cervical screening
program is not effective in curbing the incidence of cervical cancer among women in
South Africa. There are many possible reasons for the low screening rate in the country,
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including lack of education on cervical cancer prevention, transportation costs, and lack
of trained health workers. In most developing countries, such as South Africa, cytologic
screening is only accessible to a relatively small proportion of women who know about
the services and can afford to use them. Cervical cancer is a universal threat to all
women, however the incidence of cervical cancer is high in developing countries because
of the poor implementation of screening programs. Professor Denny comments that “We
[South Africa] have the same incidence of cervical cancer today than was found in
Sweden in the 1950s, and then they introduced the mass screening programs which
dramatically reduced the incidence of the disease. It’s not something special in
developing countries, it is just that we don’t screen.” She goes on to say that the National
Guidelines for cervical cancer in South Africa is merely a policy, “but not a program, and
I think we haven’t implemented it… it requires a lot of effort and political will and a
health system committed to doing that. 66 ”

IV. Bettering Women’s Health in South Africa with the Khayelitsha
Cervical Cancer Screening Project
The Khayelitsha Cervical Cancer Screening Project was established in 1996 under
the supervision of Professor Lynette Denny in order to explore alternatives for cytologic
screenings for the prevention of cervical cancer. The Project was established inside the
boundaries of the Khayelitsha Site B Day Hospital and functions out of converted
shipping containers donated by the Cancer Association of South Africa. The project is
staffed by a variety of doctors, community health workers, nursing sisters, and project
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coordinators who, in addition to performing research, provide gynecological services to
the women of Khayelitsha.
The Cervical cancer Screening Project is based in Khayelitsha because it is one of
the largest townships in Cape Town and has the population to support large-scale
research projects 67 . In addition to having a good sample size for study, Professor Denny
says “it was an area at the time with virtually no services, so we were particularly
interested in accessing women who hadn’t had pap smears and to see if we could set up
some alternative systems to pap smears for preventing cervical cancer. 68 ” Since its advent
in 1996, the project has screened over 16,000 women in 4 major projects and through a
free cytologic screening service to the community. The project also provides a general
women’s health service, which “ranges from helping women who are victims of domestic
violence to dealing with HIV to other common medical problems, such as diagnosing
diabetes and referring to the appropriate health care facilities. 69 ” The Cervical Cancer
Screening Project in Khayelitsha exposes the challenges concerning the current
gynecological policies, while at the same time making efforts to improve the availability
and access of these services.

Increasing Availability of Cervical Cancer Screening Services
A research study was conducted in 1999 by the Khayelitsha Cervical Cancer
Screening Project examining the effectiveness of alternatives to cytologic screening that
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could be used for resource-poor settings 70 . The study recruited 2944 women from
Khayelitsha between the ages of 35 and 65 years. The women were screened using a
combination of pap smears, HPV DNA testing, direct visualization after application with
5% acetic acid solution (VIA), and cervicography to evaluate the sensitivity and
specificity of each the techniques. Women with squamous intraepithelial lesions were
referred for further treatment to receive a colposcopy.

A. Visual Inspection with Acetic Acid (VIA)
Visual inspection with acetic acid is the most widely evaluated visual screening
test for squamous intraepithelial lesions. A solution of 5% acetic acid can be applied to
the cervix with a cotton swab and lesions appear acetowhite to the naked eye after 1 to 2
minutes 71 . VIA is inexpensive, requires only acetic acid and a light source, involves little
training, does not need a laboratory infrastructure, and yields results in a matter of
minutes. The mechanism of action entails a chemical reaction between the acid and
cellular proteins, causing coagulation 72 . Areas of increased nuclear activity and DNA
content, such as cervical neoplastic cells, show the greatest protein precipitation. High
levels of coagulation block the normally red stroma of the cervix and are visualizing as
white lesions along the transformation zone. Normal squamous epithelium does not show
coagulation because the superficial layer of the epithelium is sparsely nucleated, and this
contains a low cellular protein content. In the study, VIA was accompanied by
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cervicography 73 as a means of quality control to ensure the best possible reading, and
2.5X magnification using a handheld magnification device in order to see whether
magnification of the cervix yields better results. VIA was found to have equal sensitivity
to cytology, with the ratio of VIA to cytology being 0.85, however, VIA was found to
have lower specificity, with the ratio of false-positive rate of DVI to cytology being 4.7 74 .

B. Visual Inspection with Lugol’s Iodine (VILI)
Visual inspection of the cervix can also be done with the application of Lugol’s
Iodine (VILI), which is similar to the Schiller’s iodine test used in the 1930s and 1940s
for detecting cervical neoplasia 75 . In this procedure, iodine is applied to the cervix in the
same manner as acetic acid, however the mechanism by which iodine operates is
different. VILI depends on the interaction between iodine and glycogen 76 . Squamous
metaplastic epithelium is abundant with glycogen and iodine is glycophilic. Therefore,
application of iodine to the cervix results in the uptake of iodine into the cells, turning
healthy squamous epithelial cells dark brown. Cervical intraepithelial neoplastic cells are
poor in glycogen, since abnormal cells have a high ratio of nuclear to glycogenated
material. These abnormal cells are visualized as mustard-yellow upon inspection 77 . VILI
has equal specificity as and greater sensitivity than VIA 78 . Both of these techniques are
routinely used as colposcopic techniques to visualize lesions that require biopsy or further
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treatment, however, research completed by organizations such as the Khayelitsha
Cervical Cancer Screening Project have looked at these methods as alternatives to
cytologic screenings as well. Visual inspection with acetic acid is used by colposcopists
to evaluate the grade of lesions 79 . CIN I lesions appear as small, white pimples. CIN II
lesions appear as large, white patterns. CIN III lesions appear as large, solid white
portions of the cervix. Visual inspection with Lugol’s Iodine is used to show well-defined
borders of lesions regardless of the grade of the lesion 80 . Application of iodine is
especially useful for removal of lesions using LLETZ since the entirety of the lesion is
exposed.

C. HPV DNA Test
The HPV DNA test used by the cervical cancer screening project is a biochemical
test that detects viral protein markers for certain strains of HPV DNA, specifically “high
oncogenic risk 81 ” HPV types 82 . HPV DNA screening test was performed using two
sensitivity markers- a high positive cut-off was defined as samples containing at least 10
times as much HPV DNA as the positive control (>10X), while a low positive cut-off
was defined as any sample containing HPV DNA greater than the control (>1X). HPV
DNA testing at a low cut-off was found to be as sensitive as cytology, however, HPV
DNA testing at a high cutoff was found to be as specific as cytology. HPV DNA testing
would be useful for low-resource settings because it does not require skilled laboratory
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technicians to evaluate the results and is easier to perform than cytology 83 HPV DNA
Testing would also be useful because it identifies not only women who have lesions, but
women who have the greatest risk of developing precancerous lesions and can be
followed up more closely than other women. The disadvantages lie in cost, and require
laboratory and storage facilities for samples.

Total
Treated
8.1
18.1
16.2

Correctly
Treated
High grade SIL
or carcinoma
2.6
2.1
2.3

Correctly
Treated
Low grade SIL

Overtreated
No disease

2.1
3.4
Cytology
1.7
14.4
Direct Visual inspection
2.2
11.7
HPV DNA (standard cutoff
RLU > 1X positive control
6.1
1.5
1.5
3.0
HPV DNA (high cutoff RLU
> 10X positive control)
10.5
2.0
1.7
6.8
Cervicography
Table 4.1: Proportion of women screened who would be treated correctly and those who would be
overtreated by each screening test in the absence of colposcopy, as performed by the Khayelitsha Cervical
Cancer Screening Project 84

D. Evaluation of Alternatives
These alternative methods of cervical cancer screenings, however, have yet to be
considered as national policy for a variety of reasons. According to Professor Denny, “To
this point, [these methods] have all been experimental. It takes a long time to prove that
your intervention is going to be successful. I think the reason why it hasn’t been
implemented in South Africa is because there hasn’t been that much data or knowledge,
and now that’s all coming out… It’s a question of translating research into practice. 85 ”
Cervical cancer screening alternatives are currently not offered at the Project because as a
research institution, they must offer state regulated services to women and cytologic
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screenings remain the approved method of screening by the Department of Health. Olivia
Briton, one of the Project Coordinators for the Khayelitsha Cervical Cancer Screening
Project commented that the HPV DNA Test used in the trials in 1999 would not be
implemented in South African national policy because it is more expensive than a pap
smear 86 . While a pap smear may cost around R100 – R200, the HPV DNA test for
cervical cancer costs around R200 - 300 87 . Other limitations of the use of HPV DNA
testing are the possibility of overtreatment. HPV DNA testing only tests if high-risk
strains of HPV are present, not cervical lesions. Some women may present with high-risk
HPV DNA, but may not actually have any cervical abnormalities. Professor Denny
suggests that this may not be a problem, however. “We know we are overtreating
women,” she says, “but we didn’t show an increase in severe complications and women
found it very tolerable and acceptable in our experience. 88 ” While HPV DNA testing may
not be a useful alternative due to cost and infrastructure issues, visual inspection with
acetic acid “wasn’t more expensive, but that didn’t prove to be as effective as doing the
HPV DNA testing,” according to Olivia Briton. Visual inspection with acetic acid must
be closely monitored, due to the subjective nature of the test, as opposed to the objective
results obtained through HPV DNA testing, however, “if you’re in a low-resource setting,
and you’re really out in a rural area with absolutely nothing, then yes, [visual inspection
with acetic acid] is definitely better 89 .” While these alternative methods are not
necessarily appropriate for large urban areas where cytologic services are available, these
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screening methods could be used in areas like the Eastern Cape and Mpumalanga, where
they lack the infrastructure to make cytologic services available to their female
populations. While visual inspection with acetic acid may not be the most effective
screening technique, Dr. Paul Blumenthal from Johns Hopkins University comments that,
“Cervical cancer prevention is not about doing the best test. Cervical cancer prevention is
about doing the best test that you can do 90 ” and in some low-resource settings, VIA may
be the best test available.

Increasing Access of Cervical Cancer Screening Services
A. Transportation
Cervical cancer screenings do not merely involve cytologic testing, it requires that
the patient return for results, and if abnormal cytology is found, then they must go for
treatment. In Khayelitsha, it is particularly difficult for women to return to the clinic for
their results because of time constraints and transportation costs. Research is currently
being done at the Khayelitsha Site B Day Hospital to evaluate the return rate of patients
who receive pap smears. Current findings are suggesting that the “return rate for patients
coming for pap smears is extremely low and you find that people just don’t come back to
see their results 91 .” Professor Denny believes one of the reasons why women don’t return
for their results because it is difficult to access facilities, especially when there “could be
a sick relative, there could be work issues, there could be children issues. There are a lot
of logistical issues that need to be dealt with. It’s not as easy as popping into a car or
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popping into the underground and going to the next place. It is more complex 92 .” The
Khayelitsha Cervical Cancer Screening Project assists their patients and study subjects
with an informal transport system run by the community health workers of the project 93 .
Ayesha Sassman, one of the Study Coordinators at the project, says merely picking them
up is not enough to have patients return for follow-up visits. She stresses the importance
of tracing study individuals and maintaining contact to ensure their return to the clinics
for follow-up visits. She says, “They don’t generally come back so we need to coax them
a bit- give them a call or two, sometimes go out tracing them in the car to try and find
them, and often they don’t come back and you need to either call them or leave them
messages on their phone 94 .” Most clinics in South Africa, however, do not possess the
infrastructure to trace their patients or retrieve them from their homes, so the efforts made
by the Khayelitsha Cervical Cancer Screening Project represents a very special
arrangement between the research institution and the community they serve. Professor
Denny comments that this is one of the ironies of research. “Research is always much
more richly supplied with resources and there is absolutely no doubt that the women in
our project get a much better deal.” She admits, “It’s not really sustainable though. It’s
fine once you’ve got funding but you cant really supply that kind of service on a
sustainable basis unless you were in an extremely well-resourced community 95 ,” in
which townships, such as Khayelitsha, that is not necessarily the case.
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B. Access to Treatment Centers
If screening services are hard to come by in rural, low-resource areas, than
treatment centers are almost non-existent. Colposcopy services are only offered in tertiary
centers. According to Professor Denny, “Throughout the nine provinces in South Africa,
colposcopies are limited to the major hospitals 96 .” This becomes a problem in using
cytology-based programs because the next step in treatment is referral to a colposcopy
clinic. For the inhabitants of Khayelitsha, the nearest colposcopy clinic is located at
Groote Schuur Hospital in Cape Town, approximately 30 kilometers away. In places like
the Eastern Cape, which is predominantly rural with few resources, primary healthcare
institutions are the major source of treatment for patients. According to Olivia Briton,
anything requiring treatment of cervical neoplastic lesions “means that [the patients]
pretty much have to go to Port Elizabeth, and even then they don’t necessarily receive the
treatment and must go to Cape Town 97 .” In Khayelitsha, this situation has been rectified
by providing tertiary-level colposcopy services at the Cervical Cancer Screening Project.
Patients do not have to spend money on transportation into the city, and it also relieves
some of the burden on the local hospitals. Sister D. 98 , the chief professional nurse from
the project, says, “at the Day Hospital, one [healthcare provider] has to see 80 people in a
day and how are you going to get through all 80 unless you give each of them 15 to 20
minutes of your time? 99 ” Dr. Claire Flowaday from the project explained that it is very
uncommon for clinics to offer colposcopy because most gynecologists in South Africa
are only trained in colposcopy for 2 weeks. Because of this, even trained gynecologists
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usually refer their patients to colposcopist specialists for treatment 100 . Dr. Flowaday has
been training under Professor Denny for the past 6 months and provides much-needed
colposcopy services to the community of Khayelitsha through the project.
Dr. Blumenthal said, “Testing by itself has no intrinsic preventative value. It is
only by linking testing to treatment that you close the circle of prevention 101 .” Screening
for cervical cancer, either by cytologic, VIA, or HPV DNA testing, is useless if women
are not accessing the proper treatment. A solution to this problem may lie in an
innovative approach to cervical cancer screening and treatment known as the “screenand-treat” method. Research has recently been completed in establishments such as the
Khayelitsha Cervical Cancer Screening Project to examine the safety and efficacy of this
new approach.

C. The “Screen-and-Treat” Approach
The “screen-and-treat” approach involves screening women for atypical cervical
squamous cells by using VIA, VILI, or potentially, HPV DNA testing. VIA and VILI
offer immediate results, and so instead of referring the patient for colposcopy at a tertiary
clinic, one would eliminate the diagnostic step and treat patients in the same visit using
cryotherapy 102 . Unlike LLETZ, the standard procedure in hospitals in South Africa,
which surgically excises the affected cervical tissue, cryotherapy, involves freezing the
abnormal cervical tissue with a liquid coolant, such as carbon dioxide or nitrous oxide 103 .
Cryotherapy has been used for over 40 years as a method of treatment for cervical
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dysplastic cells and is considered to be “safe, feasible, acceptable, and effective” in lowresource settings 104 . Cryotherapy doesn’t require electricity and uses simple, inexpensive
equipment that can be used by trained non-physicians, such as midwives and nursing
sisters. The procedure is painless, thus requiring no anesthetic, with a cure rate of cervical
lesions being 89 – 95% 105 . While cryotherapy is a safe, effective mode of treatment for
moderate lesions, it may be less effective for large lesions that cover over 75% of the
cervix or those that extend into the endocervical canal 106 . Patients with advanced-stage
cervical lesions should be referred to the proper treatment centers, so it is preferable to
detect early lesions for the screen-and-treat approach to be most cost effective. The
“screen and treat” approach is considered to be cost-effective and cost-saving in that “the
costs of implementing a program are less than the amount currently spent on caring for
women with cervical cancer because they eliminate costs associated with follow-up visits
and loss to follow-up 107 .”
The use of HPV DNA testing followed by cryotherapy yields a greater decrease in
the incidence of cervical cancer than other alternative methods, however cost and the
need for follow-up visits makes implementation of this method difficult. A new HPV
DNA test, however, is being manufactured and will be available in the near future. The
new test, careHPV made by QIAGEN 108 , costs $5.00 per test and does not require as
much laboratory infrastructure as the previous test. According to Professor Denny, “It’s
done on site and requires two and a half hours to get a result… A woman comes in, you
take a sample, you test her, she waits two and a half hours, and if it is positive you do
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cryotherapy 109 .” While this new method of cervical cancer screening appears promising,
Ayesha Sassman from the project points out that even though it costs $5.00 per test, you
have to consider that you must first “convert $5.00 into South African rands. It is one
thing that it is costing you in dollars, but you have to multiply that by 8, depending. Once
again it becomes something that, with these exchange rates, it cannot be done 110 .” Olivia
Briton believes that it could eventually be implemented as a screening policy in South
Africa, but “it will take some time 111 .” It takes time and effort to convert research into
national practice, but if the “screen-and-treat” approach can be properly implemented, it
would provide many women with an accessible treatment method that would eliminate
complicated infrastructure and unnecessary transportation requirements.

Education and Training
A. Training Healthcare Providers
Many of the reasons why cervical cancer screening programs are not properly
implemented in some areas may be due to insufficient training and education of
healthcare providers. When the Khayelitsha Cervical Cancer Screening Project began in
1996, there were virtually no gynecological services offered to the community.
According to Olivia Briton, “We’ve basically set up the services for them 112 ,” teaching
nursing sisters and doctors in and around the Day Hospital how to perform pap smears
and gynecological examinations. In previous studies, participating doctors taught
theoretical and practical training courses for healthcare workers in the Day Hospital. The
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Cervical Cancer Screening Project also works closely with the Day Hospital, offering
expert help and advice to the healthcare workers. The chief professional nurse, Sister D,
who was also trained by the project as a colposcopist nurse, helps train other nursing
sisters how to perform pap smears. Most of the healthcare workers come to the screening
project for training. She explains that the nursing sisters “were trained to do pap smears
during their training, but they haven’t been practicing, so its about honing the skills that
they already have and showing them the right procedure in taking cervical smears.” She
goes on to say that “Sometimes it is difficult for the hospitals and the day hospitals to pull
staff out to go to training courses, so at least if we are here at the primary healthcare
setting and they do have people that are interested, they are more than welcome to come
in and polish their skills 113 .” Not all primary healthcare facilities offer training to the
extent of the Khayelitsha Cervical Cancer Screening Project; however, this provides an
example of a successful intervention that, if proper training is put into place, a successful
service can be offered to the community.

B. Community Education and Advocacy
Community education is also important for the development of successful cervical
cancer screening programs to emerge. Professor Denny believes that one of the major
reasons why cervical cancer screening programs fail in South Africa is because women
are not informed about what a pap smear is and its significance in women’s health. “They
just have a pap taken and are told to come back, but the don’t get told why,” she says,
“And if you have a screening process, you need to inform women, and I think we are
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very bad at doing that 114 .” Phumzile 115 , a 29-year old patient presented at the colposcopy
clinic at Groote Schuur Hospital on April 17, 2009, had confirmed HSIL and received
LLETZ treatment for her lesions 116 . Her doctor suggested she receive a pap smear in
2002, when she first found out about her HIV status. She was not informed in what a pap
smear entailed and had heard rumors from her friends that the procedure was very
painful. She commented, “The sisters at the clinic are rough,” but was grateful for the
intervention, stating, “I had to go because I need to know I am ok, that I am healthy 117 .”
Another patient presented at the hospital, Thembi 118 , was a 28-year old HIV-negative
woman who returned for a check-up after her LLETZ procedure. She received her first
pap smear in 2003 because she had an STD and said she was not intimidated by the
procedure the first time, explaining, “How could I be scared about something I know
nothing about? 119 ” She too was glad for the intervention because it was an opportunity to
learn more about her health. Thando is a 31-year old mother living with HIV. She had
heard about pap smears previously, but the clinic told her she could not receive one until
she turned 30 years old. She received her first pap smear a year ago, around the same
time she discovered her HIV status. High-grade lesions were confirmed in biopsy, and
she was presented at the colposcopy clinic to have her lesion removed by LLETZ. While
she was glad to have had the procedure performed, it is unfortunate that she had
attempted to receive a pap smear in earlier years, possibly when she had low-grade
lesions, as opposed to the high-grade lesions found in her first pap smear. Regardless,
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Thando said, “I’m sore [from the procedure], but I’m happy to have it done because I
know people die from cancer 120 .” These testimonies show that with proper information,
women are happy and willing to access gynecological services. Professor Denny
commented “if a woman knows that she has an abnormality in her cervix that could cause
cancer, she’ll be [at the clinic] pretty quickly for treatment 121 .”
Evidence from Khayelitsha suggests that if women are informed and reminded
regularly about their gynecological appointments, then they are more likely to return for
follow-up visits. According to Professor Denny, “in our situation, in my study, women
knew why they had to come back and we had a very high return rate122 .” Project
Coordinator, Ayesha Sassman, echoes this sentiment, saying, “For the purposes of this
study we are obliged to cover all the bases… Obviously we have a better return [for the
study] because we go and find them and we call them and leave messages.” While the
members of the cervical cancer screening project are not obligated to expose as much
information to non-study patients, “we always tell them everything and why its important
to come back, why results are so important to know about. It’s choice 123 .” The chief
professional nurse, Sister D. also believes that the studies have been important for
exposing women to cervical cancer screenings, saying that women from previous studies
return for screenings later in life. “We still get clients. A study concluded in 2006 when
the data was closed, but we still get clients coming in for all sorts of things, like when
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they would have lower abdominal pain 124 .” The project’s presence in community has
been an educational source for the women of Khayelitsha. The more women who become
acquainted with the studies and services offered, the more likely they will share this
information with their neighbors and friends. Ayesha Sassman commented “Professor
Denny has been in this community for 13 years, so we are well known. We are known as
the ‘womb people,’ the ‘healers of the womb,’ so women come here to get pap smears, or
they come here to get their wombs cleaned so they can have babies 125 .” Besides word of
mouth, the members of the Khayelitsha Cervical Cancer Screening Project reach the
women community through local television and radio broadcasts. Radio Zibonele. The
radio station serves the population of Khayelitsha and features a health program on
Tuesdays where nursing sisters and community health workers from the project visit to
talk about the importance of pap smears and getting screened 126 .

C. Language and Health
Language also functions as an important aspect of education and advocacy in the
township of Khayelitsha. The mother tongue of most individuals in the community is
Xhosa, and it is particularly worthy to educate women about the importance of cervical
cancer in this language to the community. Ayesha Sassman, a white woman, spoke about
recruiting patients for the study at the project, saying, “I’ve gone out addressing crowds
and they’ve just stared at me blankly with no responses… It’s definitely better to have
people conversing in the language that the people understand and that they are
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comfortable 127 .” Phumzile, the colposcopy patient mentioned earlier, said that her
English is not proficient, but must learn to speak it in order to talk to most people.
Professor Denny takes great care in ensuring her clients understand what procedures are
being performed on them. She speaks Xhosa, but not with as much depth as she would
like, however it is impossible for a patient to fully understand her in English if it is their
second language. For this reason, she has a nursing sister assist her with her colposcopies
who is fluent in Xhosa and can fully explain the procedures to her patients 128 . Many
English vocabulary words for gynecological terms are very different in Xhosa and
English, making English explanations difficult. For example, the word “cervix” in Xhosa
is umlomo wesibeletho, which literally translates to the “mouth of the womb,” and so if a
medical practitioner were to explain cervical screenings, the patient may not understand
to what she is referring. The Khayelitsha Cervical Cancer Screening Project ensures that
women participating in studies are read consent forms in Xhosa by a first-language
Xhosa-speaking sister. The Project is staffed by community health workers and nursing
sisters whose first language is Xhosa. When women receive pap smears or colposcopic
examinations at the project, the doctors ask the patient if she would like someone to
explain the process in Xhosa so that they are able to fully understand the procedures 129 .
In the Day Hospital, the family physician allows medical school students from the
Stellenbosch Medical School to meet with patients and present their symptoms to the
physician. Students were observed taking the medical history of the patient and assessing
their symptoms, however, when they came across a puzzling aspect of the examination,
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they proceeded to speak to each other in Afrikaans, which some of the patients did not
understand. Patients appeared uncomfortable with this intervention because they were
unable to understand what the medical students were discussing with one another 130 . Full
disclosure to patients in a language they understand is key for creating a safe and
comfortable environment for both the patient and the healthcare provider. Fortunately,
schools like the Stellenbosch Medical School and University of Cape Town School of
Medicine are now incorporating Xhosa into the first year curriculum, allowing students to
be able to communicate to a certain extent with the majority of the Western Cape
community.

Organization and Advocacy
A. Patient Information
Research concerning cervical cancer screenings and innovative programs for lowresource areas has recently been a new development. Statistics concerning cervical cancer
incidence and mortality over the years, in addition to HPV prevalence in South Africa is
difficult to come across, and many of these are non-existent. Belmira Rodriguez, the
African Operations Manager from the African Organization for Research and Training in
Cancer (AORTIC), says, “We don’t have proper statistics- it is quite outdated 131 .” Within
the Khayelitsha Site B Day Hospital, files and patient information and poorly organized.
Patient cytologic reports are loosely alphabetized and disorderly. On one occasion, a
patient returned for her cytologic report, but the results had yet to be processed, so the
patient had to return the next week to retrieve her report. When the second patient arrived
to receive her cytologic report, she did not have her personal file and thus had to return in
130
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a week to obtain her report. Patient information was maintained on a database at the
cervical cancer screening project, but was not immediately accessible to the pap sister at
the Day Hospital. Denny comments, “it’s a disaster. It’s just so badly organized and
that’s something that I have brought to the attention of the authorities and we’re going to
tackle it.” While the Day Hospital and the cervical cancer screening project associated
with it do not have abundant resources for a sophisticated logging system, Professor
Denny rebutted, “It is bad management. It doesn’t matter where you work, you can
always have a system. There are no excuses. It is just sloppiness 132 .” Organization of
patient files is vital for tracking and monitoring the health and behavior of these
individuals. Sister D. From the project in Khayelitsha says, “It all boils down to taking
adequate history, of which I think the public health service to that extent fails.” If a
patient presents with lower abdominal pain and requests a pap smear to detect cervical
cancer, it is necessary to evaluate her medical history to see if there are any other
underlying problems that can aid in diagnosing and treating the patient. “If they had their
last pap smear 6 months down the line and now she wants another pap smear, you must
use your discretion because it means nothing would have changed from 6 months to
now… you would have to be assessed for something other than cancer of the cervix 133 .”
Proper bookkeeping and organization would ensure that resources are being used for
proper testing and treatment.
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B. International Organization
Efforts are also being made to organize cancer organizations and clinics on a
global level. AORTIC is currently working with a Pfizer fellow to locate cancer
organizations on the continent of Africa 134 . Currently, there are about 4,000 organizations
in the database, but it has been difficult to find most of the clinics and organizations
because many of them don’t have websites or phone numbers. The aim for this database
is to incorporate more African representatives for cancer conferences and to profile the
activity of each organization. According to Belmira Rodriguez, the Africa Operations
Manager of AORTIC, there is a lack of collaboration among organizations because they
compete for funds. If these organizations could work together to push cancer as a
legitimate healthcare issue, national governments throughout Africa may begin to
allocate resources to effective cancer policies. Within South Africa, there are a few
isolated projects throughout the country, in addition to the cervical cancer screening
Project in Khayelitsha, performing research on cervical cancer screening strategies in
East London and Limpopo, however there are no organized coordinated efforts being
made to campaign for effective cervical cancer screening policies.

V. The Future of Research for Cervical Cancer Prevention and
Treatment
The HPV Vaccination
While much research has been done concerning secondary methods of cervical
cancer prevention, including alternative methods for screening and single-visit
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approaches to increase the number of women accessing gynecological services, new
research is now being conducted looking at primary prevention methods, namely the
HPV vaccination. The Khayelitsha Cervical Cancer Screening Project is conducting the
first study to evaluate the safety and efficacy of the HPV vaccine, Cervarix, on HIVpositive women. Studies suggest that HIV-positive women are at an increased risk of
acquiring HPV, making them more susceptible to developing cervical cancer. As HIVpositive women are living longer due to antiretroviral treatment, it is necessary to look at
the opportunistic infections, such as cervical cancer, that will affect HIV-positive women
in the future.
The HPV vaccine has been shown to be effective in reducing the rates of initial
infection with HPV-16 and HPV-18, the two HPV strains responsible for 70% of cervical
cancer-related infections, in healthy young women. The safety and efficacy of the
vaccine, however, has not been documented in immunocompromised individuals. Before
any future large-scale immunizations can take place, studies must be done to ensure that
HIV-positive women will accept the vaccine, since these are the women that can benefit
most from this form of therapy. Professor Denny points out that the vaccine creates a
“hyper-immune environment 135 ,” and if women with damaged immune systems, like
those living with HIV/AIDS, than the vaccine may not be as effective as in HIV-positive
patients as it is in HIV-negative patients. Joel Palefsy suggests, however, “theoretically,
there should be relatively little impact on humoral immune responses in HIV-positive
women… but it is not known if these women will remain protected 136 .” Studies must first
address whether or not the vaccine will be safe for HIV-positive women before
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addressing its efficacy, which the Khayelitsha Cervical Cancer Screening Project hopes
to establish.
The study, sponsored by the Cervarix manufacturer, GlaxoSmith Kline (GSK)
Biologicals, S.A., is in its early phase of research. The Khayelitsha Cervical Cancer
Screening Project is currently recruiting HIV-positive and HIV-negative women between
the ages of 18 and 25 in Khayelitsha for the study. Professor Lynette Denny is acting as
the Principle Investigator with Ayesha Sassman and Olivia Briton acting as Project
Coordinators. Recruitment is done through local radio stations, community newspapers,
church groups, adult education centers, shopping malls, clinics, and hospitals in the area
surrounding Khayelitsha 137 . Ayesha Sassman says the most recruitment success has been
found through the youth centers. “It’s the age group we are looking for so we are
concentrating our efforts on them 138 .” The women that generally go out for recruitment
are the community health workers and nursing sisters. Ms. Sassman emphasized the
importance of having Xhosa-speaking women recruit the participants because it makes
the participants more comfortable with the study 139 .
The volunteer recruitment process through the youth clinics are done
predominantly through the Khayelitsha Site B Youth Clinic, which is close to the
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Cervical Cancer Screening Project site, and the Khayelitsha Site C Youth Clinic. The Site
B Youth Clinic is usually packed with young adults waiting to see the nursing sisters. On
one occasion, a young girl was seen performing male and female condom demonstrations
for the men and women waiting in line. The patients were engaged in the demonstration,
asking questions and making suggestions to the woman. After her demonstration, one of
the community health workers from the project stood up and discussed HPV vaccinations
and the study at the Cervical Cancer Screening Project in Xhosa and asked for those
interested to meet her after the discussion. One interested woman made plans to meet
with the community health worker for an initial evaluation later that week. The Site C
Youth clinic, which was further away, functioned as a duel youth clinic and youth center.
The clinic was spacious with brightly colored walls and had a pool table in the waiting
room. On one side, there was a door labeled “The Chill Room” which was used for health
education. While there were no candidates at this youth center, one of the community
health workers stressed the importance of these facilities. “People don’t want to go to the
clinic and see their mother’s neighbor there. They use these clinics. The resources are
here and available, so it is up to the individual to use them 140 .” While Khayelitsha
remains an under-resourced community, it is apparent that many efforts have been made
in recent years to make health services available to the public, with the development of
the Day Hospital and the Youth Clinics that appear to be well-used.
The recruitment criteria for HIV-positive women have been the most challenging
aspect of the study. Some of the criteria require that women be generally healthy, have
had at most 6 sexual partners, not be pregnant, nor have had tuberculosis (TB), or
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HPV 141 . According to Olivia Briton, “We’ve got the patients and recruitment is going
well, but because of the criteria being so strict, it’s jolly difficult to get the required
number of eligible patients into the study 142 .” There has been an 80% screening failure,
suggesting that women are interested in being a part of the study, but due to criteria
constraints, many cannot participate. She says that some of the eligibility criteria that has
been most difficult to satisfy includes women who already have cervical diseases and
women who are in stage advanced stages of HIV who “just aren’t healthy enough to
participate in this study. Most research studies, you need healthy participants 143 .” Ayesha
Sassman says that the criterion that excludes most participants is “definitely the amount
of sexual partners. Keep in mind, we are looking at women who are between the ages of
18 and 25, with 6 being the maximum amount of sexual partners. That is by far the one
that trips us up every single time 144 .” This eligibility requirement is important because
the more sexual partners an individual is exposed to, the greater risk one has of
developing different strains of HPV. The project requires that there be 30 HIV-positive
and 20 HIV-negative participants in the study, however, the strict criteria is proving to be
a major obstacle in continuing the study.
While the HPV vaccine revolutionizes primary prevention of cervical cancer,
implementation of the vaccine will prove to be difficult in the South African context. The
major barrier to large-scale HPV immunization programs is cost. A full course of HPV
vaccinations will cost $360 per person, which is more than most people in South Africa
are able to afford. Professor Denny notes that “The Hepatitis B vaccine was available in
141
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the developed world for 20 years before it came to the developing world, and it was only
until it came down to 25 United States cents a shot did it become widely available 145 .”
The lack of research done on the vaccine also makes it difficult to assess its usefulness in
the future. Ayesha Sassman comments that “It’s only been 2 years and we don’t have a
lot of data yet. It’s too soon to say if it’s going to be widely used because the results are
not in yet 146 .” Professor Denny says that because the HPV vaccine is preventative, as
opposed to therapeutic, “to see the benefit of the vaccine, you will need to wait a while,
for 30 or 40 years 147 .” In addition to cost and research shortcomings, the HPV vaccine
may be difficult to implement in rural areas because the full course of the vaccine
requires 3 shots spread out over time, which may be difficult for adults to obtain because
of transportation difficulties. Despite these setbacks, the HPV vaccine shows a lot of
promise in curbing the incidence of cervical cancer by stopping it at its source. This could
provide valuable preventative treatment for women at high risk of developing cervical
cancer. The first step, however, is to provide the research that establishes its importance
as a preventative tool that is safe and effective for women to use.

Conclusion
Dr. Mahmoud Fathala, the former president of the International Federation of
Gynecology and Obstetrics (FIGO) once said, “Women are not dying because of disease
we cannot treat… they are dying because societies have yet to make the decision that
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their lives are worth saving 148 .” Cervical cancer is a preventable disease that women,
predominantly in developing countries, are still dying from. Cervical cancer is the second
most common cancer to affect women in Africa, destroying the lives of mothers,
grandmothers, wives, daughters, sisters, and friends. While small organizations, such as
the Khayelitsha Cervical Screening Project, have implemented programs to make cervical
cancer screening and treatment services available to local communities, South Africa
requires national mobilization on the part of society to demand that cervical cancer be
considered as a legitimate threat to the livelihoods of women all over the country.
Research has proven that it is possible to prevent cervical cancer in low-resource settings
without the expensive infrastructure required from cytology tests, and while these
methods may not be applicable to the urban townships in the Western Cape, these
services could be implemented in the rural areas of the Eastern Cape and Limpopo where
gynecological services are scarce.
The cost of radiotherapy, which is recommended to treat all forms of cancer, is
$250,000 to set up and $35,000 annually to treat about 1,000 patients per year. If the
annual number of new cervical cancer cases is 6,742 149 , than it would cost approximately
$245,000, or about R 2,450,000 per year to treat invasive cancer using radiotherapy 150 .
This would also require specialized radiation oncologists and physicists and risks
significant morbidity. These costs, in addition to the amount allocated for the cervical
cancer screening policy currently in place, amounts to a huge sum that creates a financial
and medical burden on the country. New research is pointing towards an HPV DNA test
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that would cost $5 per test, and if used in conjunction with cryotherapy, it could provide
screening and treating services in one visit. If more women are educated about screening
and can access these services easily, than the incidence of cervical cancer would drop
significantly, thus decreasing mortality rates. If this were to happen, the government
would not have to spend R 2,450,000 every year treating preventable cervical cancer.
According to Professor Lynette Denny, “You’ve got to set up infrastructure and
you’ve got to get government on your side. South Africa believes it has the capacity to do
pap smears, although in reality that has not happened 151 .” Evidence shows that the
current national policy is not effective in curbing cervical cancer in South Africa and
research is proving that screen and treat approaches with a cheaper HPV DNA test in
addition to cryotherapy is effective and requires little infrastructure. The only work that is
left to do is to “get the government on our side.” According to Sister D. from the Cervical
Cancer Screening Project in Khayelitsha, “reproductive health has the least speciality that
is not getting a lot of attention in the healthcare system… because it is reproductive
health, it is not seen as a priority, and all illnesses should be treated as equal and the
same.” Sister D. believes that “we need a vigilant female higher up that would press the
matter as a matter of urgency because it doesn’t get attention 152 .” With international
organizations advocating effective cervical cancer policies across the globe and with the
availability of the HPV vaccine, cervical cancer may be meeting its end, but there is a
long way to go. “I think we are looking at this at a very critical juncture in history,”
Professor Denny explains, “We’ve only been able to prevent cervical cancer up to this
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point using secondary prevention. Now we have primary prevention with a vaccine but
it’s still very elusive… and there’s a lot of work to be done, but there’s a lot of hope 153 .”
The tools with which to act are currently available to prevent cervical cancer and
eradicate the disease. It is now “up to society,” as Dr. Fathala said, to use these tools and
advocate for change.
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Limitations of the Study
The information obtained through the Khayelitsha Cervical Cancer Screening
Project provided valuable insight into the challenges facing proper implementation of a
cervical cancer screening program in South Africa and into research being done to better
the status of gynecological services in the country. Data obtained through the project
represent the biases of the members of the organization and of the institutions that fund
their research. While the Cervical Cancer Screening Project has made a great difference
in the community of Khayelitsha, it represents a unique arrangement between academics
and health providers and possesses resources that are not available to the majority of
clinics in this country. The project’s success is in part due to its proximity to the
University of Cape Town and Groote Schuur Hospital, making a similar project
irreproducible in most settings outside of Cape Town. While the project has been able to
increase access, availability and education concerning cervical cancer screenings, this is
not necessarily the case for other clinics and research organizations in the country.
The Western Cape, which has access to the greatest number of resources, has
implemented a cervical cancer screening policy that differs from the National Guidelines
concerning cervical cancer screenings, so the data presented represents cervical cancer
screening programs unique to the Western Cape. In addition, the township surrounding
Cape Town, where the project is based, caters to a predominantly urban, Xhosa-speaking
population, and the cervical cancer strategies implemented were adjusted to meet the
needs of this specific community of women.
It was difficult to obtain usable information for this study concerning current
research due to confidentiality issues surrounding the HPV vaccination trials, so data was
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limited to the recruitment and selection process surrounding the study. The study
concerning the HPV vaccination among a cohort if HIV-positive women is sponsored by
the pharmaceutical company, GlaxoSmith Kline (GSK) Biologicals, S.A. Recorded
information, therefore, was carefully monitored by the Project Director so ensure the
proper representation of the funding institution and the research project itself.
Those interviewed included members of the Khayelitsha Cervical Cancer
Screening Project, and thus their opinions reflect those of the organization that the work
for. The project was initiated due to a perceived lack of resource for the community of
Khayelitsha, which may reflect biases against the current gynecological services offered
to the country. Unfortunately, due to time constraints and duration of the study, it was
difficult to create trusting relationships with patients, and so they may not have disclosed
as much information about themselves due to unfamiliarity with the facilitator.
Literary resources used for the study were obtained through cervical cancer
screening advocacy organizations, such as EngenderHealth and Jhpiego, and thus
represent the agendas of their respective institutions. Many articles obtained were written,
or co-written, by members of the Khayelitsha Cervical Cancer Screening Project. Many
of these articles were based off of studies done and the Project, and thus represent biases
associated with the organization.
The biases and opinions of the author are represented throughout the study,
reflecting her belief that all women should be given available and accessible
gynecological services regardless of her status or upbringing.
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Recommendations for Further Study
This study focused on a unique cervical cancer screening program in the Western
Cape. Despite lags in cervical cancer prevention in this province, it is one of the wellresourced, provinces in the nation. Further studies may include examining the availability
and accessibility of gynecological services offered in more rural and low-resourced
settings, such as the Eastern Cape, where some of the previously mentioned cervical
cancer screening alternatives may be more applicable. Similar research organizations to
the Khayelitsha Cervical Cancer Screening Project are currently being implemented in
the Eastern Cape and Limpopo. It would be interesting to see how effective these projects
are in providing much-needed cervical cancer screening services to the communities
there. It would also be worth looking into the differences between the quality of
gynecological services offered in the public and private sector, as well as the amount of
women in the private sector accessing these services as opposed to women in the public
sector.
One major problem presented at the Screening Project in Khayelitsha was poor
management of patient files and low patient return rates. A recommendation for further
study would be to investigate why women tend not to return for results or treatment.
Clinics and day Hospitals could be looked at as possible educational resources for women
to learn about the importance of cervical cancer screenings and treatment. Advances
within the Khayelitsha Cervical Cancer Screening Project could also be further
investigated to see the results of the HPV vaccine study for HIV-positive women.
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Summary and Review of Essential Texts
Denny, L. et al, “Evaluation of alternative methods of cervical cancer screenings
for resource-poor settings.” Cancer, Vol. 89, No. 4, August 15, 2000
Explores alternatives to pap smears, including HPV DNA testing, direct visual inspection
after application of a 5% acetic acid solution, and cervicography to find the most costeffective method for cervical cancer screening.
Denny, L. et al. “Screen-and-Treat Approaches for Cervical Cancer Prevention in
Low-Resource Settings: A Randomized Controlled Test.” JAMA, 2005
Study determines the safety and efficacy of screen-and-treat approaches as an alternative
to cervical cancer screenings. This experiment was performed at the Khayelitsha center,
and provides an important resource for the kind of work that will be done there. This
study also stresses the importance of linking screening and treating for health providers.
Denny, L., Sankaranarayanan, R. “Secondary prevention of cervical cancer,”
International Journal of Gynecology and Obstetrics, Supplement 1, Chapter 6, S65-S70,
2006.
This article defines different forms of secondary prevention for cervical cancer. Denny
and Sankaranarayan list the difficulties in implementing traditional cytologic screening
in low-resource settings and why alternative methods are more appropriate for there
settings.
Department of Health, “National Guideline on Cervical Cancer Screening
Programme,” Date unknown.
This publication gives insight on the current legislation concerning cervical cancer
screenings and provides the backdrop with which this study is conducted against.
Jhpiego, Preventing Cervical Cancer in Low-Resource Settings: From Research
to Practice, Jhpiego, 2006.
This booklet contains information discussed at the 2005 Jhpiego Conference held in
Bangkok, Thailand, examining alternative methods of cervical cancer screenings. The
book addresses advantages and disadvantages in implementing different techniques, and
offers suggestions on how different screening services can be implemented.
Kuhn, L. et al, “Human Papillomavirus DNA Testing for Cervical Cancer
Screening in Low-Resource Settings.” Journal of the National Cancer Institute, Vol. 92,
No. 10, May 17, 2000
This study evaluates HPV DNA testing as an alternative to cervical cancer screenings in
low-income settings. This provides a greater understanding of the kinds of experiments
performed by the Khayelitsha Cervical Cancer Projects. The HPV DNA test is considered
to be the most promising cervical cancer screening method for the future.
Palefsky, J. “HPV infection and HPV-associated neoplasia in
immunocompromised women,” International Journal of Gynecology and Obstetrics,
Chapter 4, S56-S64, 2006.
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This article suggests that immunocompromised women, such as those living with
HIV/AIDS, are at a greater risk of developing HPV infection and abnormal cell cytology.
Palefsky presents a multitude of studies that confirm this hypothesis. The article also
examines the possibility of using the HPV vaccine for HIV-positive women, which is
exactly what the Khayelitsha Cervical Cancer Screening Project is studying. .
Sankaranarayanan, R, Wesley, R.S., “Anatomical and pathological basis of visual
inspection with acetic acid (VIA) and with Lugol’s Iodine (VILI)” A Practice manual on
Visual Screening for Cervical Neoplasia, Chapter 1, 2003.
This source provides useful information concerning the gross anatomy and cellular
composition of the cervix. This article also describes the mechanism with which
alternative methods of cervical cancer, such as VIA and VILI, work.
Villa, LL, “Biology of genital human papillomaviruses.” International Journal of
Gynecology and Obstetrics, Supplement 1, Chapter 1, S3-S7, 2006.
This article describes the structure of HPV and how it alters normal cell cytology upon
infection. This source provides useful background reading on the development of
cancerous precursors due to HPV infection. This article also shows the importance of
proper immune responses in eradicating HPV-induced cell proliferation, suggesting a
link between immunocompromised individuals and increased risk of cervical cancer.
World Health Organization/Institut Catala d’Oncologia. “Human Papillomavirus
and Cervical Cancer: Summary Report.” WHO/ICO Information Centre on HPV and
Cervical Cancer, 2007.
This article includes relevant statistics on cancer and epidemiological factors of cervical
cancer including demographics and socioeconomic determinants. The report includes
statistical information on the incidence and mortality rates of cervical cancer. The report
also illuminates flaws in the bookkeeping system in South Africa, where vry little
statistics on HPV exist.
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Appendix A: List of Important Terms
Carcinoma in situ: High-grade squamous intraepithelial lesions that have yet to
penetrate the cervix.
Cervarix: HPV vaccine developed by GlaxoSmith Kline Biologicals, SA
Cervix: The neck of the womb where the lower portion of the uterus meets the upper
portion of the vagina.
CIN: Cervical Intraepithelial Neoplasia. Represents potentially pre-malignant
transformation and abnormal growth of squamous cells on the surface of the cervix.
Columnar Epithelium: Epithelial layer of the cervix lining the endocervical canal. Cells
secrete mucus that lubricates the vagina.
DVI: Direct Visual Inspection (also known as VIA)
Dysplastic Squamous epithelium: Abnormally matured squamous epithelium. HPV
infections cause dysplastic squamous cell maturation.
GSK: GlaxoSmith Kline Biologicals, S.A.
HPV: Human Papillomavirus. Small DNA viruses that infect various epithelial tissue,
naely those of the reproductive organs. “High-risk” strains of HPV are responsible for
99.7% of cervical cancers.
HSIL: High-grade squamous intraepithelial lesions.
LEEP: Loop electrosurgical excision procedure (also known as LLETZ)
LLETZ: Large loop excision of the transformation zone (also known as LEEP)
LSIL: Low-grade squamous intraepithelial lesions.
Metaplastic Squamous Epithelium: Newly formed, healthy squamous epithelium that
replaces columnar epithelium as the cervix ages.
“Screen-and-Treat” Approach: Cervical cancer preventative method where patient is
screened and treated in one visit.
SIL: Squamous intraepithelial lesions.
Squamocolumnar Junction: Intersection where squamous epithelium meets columnar
epithelium on the cervix.
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Squamous epithelium: Glycogen-rich epithelial layer of the cervix located on the
ectocervix.
VIA: Visual Inspection with Acetic Acid (also known as DVI)
VILI: Visual Inspection with Lugol’s Iodine
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Appendix B: Interview Questions
Questions for Principle Investigator, Professor Lynette Denny, of the Khayelitsha
Cervical Cancer Screening Project:
How did the Khayelitsha Cervical Cancer Screening Project get started?
Have there been an increase in women accessing services and education?
Besides doing research, does the project offer services to the community?
Are there any reasons why the alternatives you’ve studied haven’t been used instead of
the traditional cytologic screenings?
Why are the return rates at the Day Hospital so low?
Are there any educational services provided to encourage women to get screened?
Why do you think the incidence of cervical cancer is so high in developing countries?
How could the HPV vaccine interfere with women who are HIV positive? Are there any
considerations to give men the HPV vaccine?
Do you think South Africa has the resources to maintain the current policy?
Considering the success with Khayelitsha, do you think similar research units could be
implemented in other provinces?
What do you think it will take to make the HPV vaccine more widely available?

Questions for staff at the Khayelitsha Cervical Cancer Screening Project:
Does the Khayelitsha Cervical Cancer Screening Project work closely with the Day
Hospital?
What aspects of the eligibility criteria are most difficult to satisfy for this study?
What are some of the difficulties faced with previous trials concerning pap smears?
How do you recruit women for these studies?
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What are some of the advantages and disadvantages of the alternative screening methods?
Since the advent of the project, does it seem like more women are knowledgeable about
pap smears?
Are there any educational services offered by the day hospital?
Does the project work with training other doctors and nurses?
Why don’t you think these services arent given as much attention as other health
services?

Questions for Belmira Rodriguez from AORTIC:
Is AORTIC involved in any of the implementation strategies associated with the new
cheaper HPV DNA testing?
Is AORTIC involved in distribution of HPV vaccines for low-resource settings?
What kind of training is being done in South Africa for cervical cancer screenings?
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Appendix C:
Photographs

Photographs of the view
taken from the
Khayelitsha Cervical
Cancer Screening Project
located besides the Site B
Day Hospital in
Khayelitsha. The
township is one of the
largest in Cape Town and
houses a mainly Xhosaspeaking population. The
majority of the citizens of
Khayelitsha live in
informal housing, as
viewed here. Homes like
these stretch out as far as
the eye can see from the
Cervical Cancer Screening
Project. For most people
living in the heart of Cape
Town, Khayelitsha is
mostly seen while driving
along the highway, but for
the inhabitants here, these
photographs represent the
grim reality of poverty
and lack of resources. The
community health workers
and nursing sisters from
the project commonly
fetch patients from homes
like these, and bring them
to the project for cervical
cancer screenings and
treatment.
(Photographs taken
Thursday, April 2, 2009)
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Photographs of a typical day
inside the Khayelitsha Site B
Day Hospital. Many patients
wait in line all day to see a
health practitioner. The
Khayelitsha Cervical Cancer
Screening Project helps
alleviate the burden of the
hospital by performing pap
smears and colposcopy when
possible. The hospital is
always a busy place, however,
and patients must arrive
extremely early in the
morning to be able to speak
with a doctor.
(Photograph taken Thursday,
April 23, 2009 at 1:00 pm.)
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Location of the Khayelitsha Cervical Cancer Screening Project. The organization
operates out of converted shipping containers.

An example of one of the examination rooms inside the Khayelitsha Cervical Cancer
Screening Project containers
(Photographs taken Thursday, April 23, 2009)
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Appendix D: Important Forms and Documents Pertaining to the
Khayelitsha Cervical Cancer Screening Project

Document I: Cytology Report
Patient information is recorded on this form for cervical cancer screenings.
Document II: Histopathology Report
Cervical sample data is recorded on this report for further inspection of abnormal
cell cytology.
Document III: Patient Reminders
Notes in Xhosa are sent to the homes of patients to remind them of their next
examination.
Document IV: Non-Project Unscheduled Visit Form
Form to be filled out for un-scheduled visits if a patient feels that they are ill.
Document V: Temperature Log
Log maintains a record of the temperature of various tests, which are kept in an
office. The desired range is anywhere between 4 degrees C and 30 degrees C,
however, the metal containers during the summer can cause the office to heat up
to as great as 40 degrees C.
Document VI: Doctor’s Notice
This document is a notice signed by doctors to be given to the employers of
patients if they are too sick to attend work.
Document VII: Patient Information Form
This form is given to the patient after meeting with a health provider. The card
tells the patient what was done and when to come back. It is also useful if a
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patient decides to go to a different clinic, so that the doctors will know what
treatment they have received.
Document VIII: Non-Project LEEP Form
Form is to filled out if a patient has received LEEP treatment for cervical lesions.
Document IX: Colposcopy List
The Khayelitsha Cervical Cancer Screening Project records patients with
abnormal cervical cells.
Document X: Tracing Logs
Document tracks the whereabouts of the patients so they can be easily reached if
they require follow-up treatment. This is especially important for patients with
high-grade lesions that must be treated immediately. Tracing is a method unique
to the Khayelitsha Cervical Cancer Screening Project, not to the hospital.

